mTOR inhibitors as a new therapeutic option for epilepsy.

abstract：:Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of A...

journal_title：Expert review of neurotherapeutics

authors： Pascual J,Vila C

更新日期：2019-08-01 00:00:00

abstract：:Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

journal_title：Expert review of neurotherapeutics

authors： Sobow T

更新日期：2010-05-01 00:00:00

abstract：:Alzheimer's disease (AD) is the most common cause of dementia and is characterized by an insidious onset and slow deterioration in cognition, activities of daily living (ADL), mood stability and social functioning. The cholinesterase inhibitors (ChEIs), developed based on the cholinergic hypothesis, are currently cons...

journal_title：Expert review of neurotherapeutics

authors： Tsuno N

更新日期：2009-05-01 00:00:00

abstract：:Pseudotumor cerebri (PTC) is characterized by intracranial hypertension without ventriculomegaly, in the absence of a mass lesion or meningeal process. When there is no secondary cause, it is termed 'idiopathic intracranial hypertension'. Headache is the most common symptom of PTC, present in over 90% of patients. The...

journal_title：Expert review of neurotherapeutics

authors： Friedman DI

更新日期：2008-03-01 00:00:00

abstract：:Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

journal_title：Expert review of neurotherapeutics

authors： Rizzo R,Martino D

更新日期：2015-04-01 00:00:00

abstract：:Pain is one of the most troublesome sequelae of stroke, occurring in 19-74% of patients. A portion of this post-stroke pain is caused by the brain lesion itself; this is called 'central post-stroke pain' (CPSP). Although the prevalence of CPSP among stroke patients is low (1-8%), the persistent, often treatment-refrac...

journal_title：Expert review of neurotherapeutics

authors： Kim JS

更新日期：2009-05-01 00:00:00

abstract：:Multiple sclerosis (MS) is an autoimmune disorder characterized by CNS inflammation, demyelination and cellular damage with atrophy. Most patients with MS initially present with a relapsing-remitting course, with periodic episodes of neurologic symptomatology that do not follow a predictable pattern. In order to maint...

journal_title：Expert review of neurotherapeutics

authors： Fox EJ

更新日期：2010-12-01 00:00:00

abstract：:Spontaneous (non-traumatic) symptomatic intracerebral hemorrhage is a devastating form of stroke, with very high overall mortality and morbidity. Even with the best current medical or surgical treatment, outcomes still remain poor. By contrast with ischemic stroke, the incidence of intracerebral hemorrhage is not decr...

journal_title：Expert review of neurotherapeutics

authors： Wilson D,Charidimou A,Werring DJ

更新日期：2014-06-01 00:00:00

abstract：:Cerebral folate deficiency is defined as any neurological condition associated with low cerebrospinal fluid folate concentrations. It is becoming increasingly associated with several neurological diseases, either genetic or environmental. Treatment of cerebral folate deficiency by folate supplementation is generally e...

journal_title：Expert review of neurotherapeutics

authors： Molero-Luis M,Serrano M,O'Callaghan MM,Sierra C,Pérez-Dueñas B,García-Cazorla A,Artuch R

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...

journal_title：Expert review of neurotherapeutics

authors： Creese B,Da Silva MV,Johar I,Ballard C

更新日期：2018-06-01 00:00:00

abstract：:In the last two decades clinicians have become increasingly aware of the frequency, importance and functional impact of cognitive dysfunction in multiple sclerosis. There is, however, a dearth of research in this area. In order to further progress in the field of neuropsychological diagnosis it is essential to validat...

journal_title：Expert review of neurotherapeutics

authors： Amato MP,Zipoli V

更新日期：2002-09-01 00:00:00

abstract：:Systemic thrombolysis with recombinant tissue plasminogen activator is the first therapy proven to be effective in acute ischemic stroke. Nevertheless, its efficacy and feasibility are still a matter of debate. Much of this debate derives from uncertainties regarding patient eligibility and problems implementing this ...

journal_title：Expert review of neurotherapeutics

authors： Koennecke HC

更新日期：2002-03-01 00:00:00

abstract：INTRODUCTION:Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative disease for which there is currently no cure or approved treatment. FRDA is caused by deficits in the production and expression of frataxin, a protein found in the mitochondria that is most likely responsible for regulating iron-sulfur...

journal_title：Expert review of neurotherapeutics

authors： Strawser C,Schadt K,Hauser L,McCormick A,Wells M,Larkindale J,Lin H,Lynch DR

更新日期：2017-09-01 00:00:00

abstract：:Dystonia may be a sign or symptom, that is comprised of complex abnormal and dynamic movements of different etiologies. A specific cause is identified in approximately 28% of patients, which only occasionally results in specific treatment. In most cases, treatment is symptomatic and designed to relieve involuntary mov...

journal_title：Expert review of neurotherapeutics

authors： Bhidayasiri R,Tarsy D

更新日期：2006-06-01 00:00:00

abstract：:Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

journal_title：Expert review of neurotherapeutics

authors： Dennison L,Moss-Morris R

更新日期：2010-09-01 00:00:00

abstract：:This review evaluates the most recent evidence available on the potential of cannabinoid drugs to relieve spasticity and pain in multiple sclerosis. Many different drugs are used to control the symptoms of multiple sclerosis, periods of relapse and the progression of the disease but it is in the potential management o...

journal_title：Expert review of neurotherapeutics

authors： Smith PF

更新日期：2003-05-01 00:00:00

abstract：:Malignant gliomas comprise a small percentage of all cancers, but continue to cause disproportionate levels of morbidity and mortality. Despite decades of intensive effort from many disciplines--surgery, radiation oncology and medicine--they remain refractory to cure and, in most cases, even to prolonged treatment res...

journal_title：Expert review of neurotherapeutics

authors： Nicholas MK,Lukas R,Bangalore S

更新日期：2005-11-01 00:00:00

abstract：:Babies born to mothers exposed to antiepileptic drugs (AEDs) are at increased risk for major congenital malformations, cognitive impairment and fetal death. For the millions of women with epilepsy, maintaining the safest drug that will successfully prevent seizures during pregnancy remains a primary consideration. The...

journal_title：Expert review of neurotherapeutics

authors： Tatum WO

更新日期：2006-07-01 00:00:00

abstract：:Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...

journal_title：Expert review of neurotherapeutics

authors： Rozen TD

更新日期：2002-05-01 00:00:00

abstract：:The risk of recurrent stroke following transient ischemic attack or minor stroke has recently been shown to be 5-10% at 1 week and 10-20% at 3 months, depending on study population and methods. This is considerably higher than previously estimated and current clinical guidelines reflect the need for rapid assessment a...

journal_title：Expert review of neurotherapeutics

authors： Giles MF,Rothwell PM

更新日期：2005-03-01 00:00:00

abstract：:With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

journal_title：Expert review of neurotherapeutics

authors： Bergamaschi R

更新日期：2006-03-01 00:00:00

abstract：:Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

journal_title：Expert review of neurotherapeutics

authors： Mastrangelo M,Cesario S

更新日期：2019-11-01 00:00:00

abstract：:Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

journal_title：Expert review of neurotherapeutics

authors： Naoi M,Maruyama W

更新日期：2009-08-01 00:00:00

abstract：:Epilepsy is one of the most common neurologic disorders in childhood that often requires long term treatment with antiepileptic drugs. Both antiepileptic treatment and the comorbidities associated with epilepsy have a negative impact on bone health in growing children. Given the fact that vitamin D deficiency is a maj...

journal_title：Expert review of neurotherapeutics

authors： Cebeci AN,Ekici B

更新日期：2014-05-01 00:00:00

abstract：:Advances in molecular biology and virology in recent years have enabled the technology of gene transfer to proceed forward. Parkinson's disease (PD) is a particularly appropriate target for gene therapy since the brain pathology is fully characterized and relatively well circumscribed largely within the nigrostriatal ...

journal_title：Expert review of neurotherapeutics

authors： Mochizuki H

更新日期：2007-08-01 00:00:00

abstract：:Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...

journal_title：Expert review of neurotherapeutics

authors： Ng HS,Zhu F,Kingwell E,Zhao Y,Yao S,Ekuma O,Svenson LW,Evans C,Fisk JD,Marrie RA,Tremlett H

更新日期：2021-01-01 00:00:00

abstract：:The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

journal_title：Expert review of neurotherapeutics

authors： Davis MP

更新日期：2011-08-01 00:00:00

abstract：:The optimal therapy of pediatric ependymomas is controversial. The benefit of surgical resection is widely accepted, but the role of adjuvant therapy is subject to debate. Due to the relatively low survival rates of ependymoma patients, as well as the tumor's high recurrence rates, further research into the efficacy o...

journal_title：Expert review of neurotherapeutics

authors： Krieger MD,Bowen IE

更新日期：2005-07-01 00:00:00

abstract：:Cyclooxygenase-2 specific inhibitors have anti-inflammatory and analgesic properties, and are effective in managing a wide range of chronic and acute painful conditions such as adult rheumatoid arthritis, osteoarthritis, migraine, primary dysmenorrhea and postoperative pain. Valdecoxib, an orally administered cyclooxy...

journal_title：Expert review of neurotherapeutics

authors： Joshi GP

更新日期：2005-01-01 00:00:00

abstract：:Panic disorder is one of the most common anxiety disorders and has a lifetime prevalence of 3-5%. Panic attacks can begin at any age, but commonly have their onset in early adulthood between the ages of 20 and 40 years. Naturalistic data has shown that panic disorder has a chronic and relapsing course. Panic disorder ...

journal_title：Expert review of neurotherapeutics

authors： Dannon PN,Lowengrub K,Iancu I,Kotler M

更新日期：2004-03-01 00:00:00